In this episode, Rachel Cole, PharmD, explores the evolving landscape of medications for HIV pre-exposure prophylaxis (PrEP), spotlighting lenacapavir (Yeztugo)—a newly approved long-acting injectable option given just twice yearly. She walks through how it compares to oral therapies like Truvada and Descovy, plus other injectables such as cabotegravir. Rachel also offers practical guidance on identifying candidates for HIV PrEP, navigating lab requirements, and managing side effects.&n...
All content for Clinical Capsules is the property of TRC Healthcare and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In this episode, Rachel Cole, PharmD, explores the evolving landscape of medications for HIV pre-exposure prophylaxis (PrEP), spotlighting lenacapavir (Yeztugo)—a newly approved long-acting injectable option given just twice yearly. She walks through how it compares to oral therapies like Truvada and Descovy, plus other injectables such as cabotegravir. Rachel also offers practical guidance on identifying candidates for HIV PrEP, navigating lab requirements, and managing side effects.&n...
Don’t Let New Meds for Acute Migraine Give You a Headache
Clinical Capsules
16 minutes
1 month ago
Don’t Let New Meds for Acute Migraine Give You a Headache
In this episode, TRC Healthcare editor, Rachel Cole, PharmD, evaluates 3 new migraine treatments: Atzumi, Brekiya, and Symbravo. She'll explain their dosing techniques and how they compare to existing therapies, while providing practical guidance on clinical considerations and cost-effective alternatives for acute migraine management. **** 📝 We’d love to hear from you! Take our quick listener survey—it only takes a minute and helps us make the show even better. Plus, you’ll be entered t...
Clinical Capsules
In this episode, Rachel Cole, PharmD, explores the evolving landscape of medications for HIV pre-exposure prophylaxis (PrEP), spotlighting lenacapavir (Yeztugo)—a newly approved long-acting injectable option given just twice yearly. She walks through how it compares to oral therapies like Truvada and Descovy, plus other injectables such as cabotegravir. Rachel also offers practical guidance on identifying candidates for HIV PrEP, navigating lab requirements, and managing side effects.&n...
